Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung

Journal of Pharmacology and Experimental Therapeutics

Volumn 282, Issue 1, 1997, Pages 208-219

  Fryer, Allison ^c   Huang, Yuh Chin ^b   Rao, Gopna ^g   Jacoby, David ^d   Mancilla, Edward ^e   Whorton, Richard ^b   Piantadosi, Claude A ^b   Kennedy, Thomas ^a   Hoidal, John ^f  

^a CAROLINAS MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c The Johns Hopkins University   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Scientific Protein Laboratories   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CATHEPSIN G; HEPARIN; LEUKOCYTE ELASTASE; O DESULFATED HEPARIN; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRONCHOSPASM; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SULFATION; ENZYME INHIBITION; FEMALE; GUINEA PIG; INTRATRACHEAL DRUG ADMINISTRATION; LUNG DISEASE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; SYRIAN HAMSTER;

ANIMALS; ANTICOAGULANTS; CRICETINAE; FEMALE; GUINEA PIGS; HEPARIN; HUMANS; LUNG; MESOCRICETUS; MUSCLE, SMOOTH; NEUTROPHILS; RABBITS; RECEPTOR, MUSCARINIC M2; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030881464     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. AHMED, T., ABRAHAM, W. J. AND D'BROT, J.: Effect of inhaled heparin on immunologic and non-immunologic bronchoconstrictor responses in sheep. Am. Rev. Respir. Dis. 145: 566-570, 1992.
2. AHMED, T., GARRIGO, J. AND DANTA, I.: Preventing broncho-constriction in exercise-induced asthma with inhaled heparin. N. Engl. J. Med. 329: 90-95, 1993.
3. AHN, C. M., SANDLER, H., GLASS, M. AND SALDEEN, T.: Effect of a synthetic leukocyte elastase inhibitor on thrombin-induced pulmonary edema in the rat. Exp. Lung Res. 19: 125-135, 1993.
4. ALLEN, D. H. AND TRACY, P. B.: Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface. J. Biol. Chem. 270: 1408-1415, 1995.
5. Au, Y. P. T., DOBROWOLSKA, G., MORRIS, D. R. AND CLOWES, A. W.: Heparin decreases activator protein-1 binding to DNA in part by posttranslational modification of Jun B. Circ. Res. 75: 15-22, 1994.
6. AYALA, L. E. AND AHMED, T.: Is there loss of a protective muscarinic receptor in asthma? Chest 96: 1285-1291, 1989.
7. BARRETT, A. J.: Cathepsin G. Methods Enzymol. 80: 561-565, 1981.
8. BERGER, M., SORENSEN, R. U., TOSI, M. F., DEARBORN, D. G. AND DORING, G.: Complement receptor expression on neutrophils at an inflammatory site, the Pseudomonas-infected lung in cystic fibrosis. J. Clin. Invest. 84: 1302-1313, 1989.
9. BJORK, I., OLSON, S. T. AND SHORE, J. D.: Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In Heparin. Chemical and Biological Properties. Clinical Applications. ed. by D. A. Lane and U. Lindahl, pp. 229-256, CRC Press, Inc., Boca Raton, FL, 1989.
10. BLACK, S. C., GRALINSKI, M. R., FRIEDRICHS, G. S., KILGORE, K. S., DRISCOLL, E. M. AND LUCCHESI, B. R.: Cardioprotective effects of heparin or N-acetylheparin in an in vivo model of myocardial ischaemic and reperfusion injury. Cardiovasc. Res. 29: 629-636, 1995.
11. CASTELLOT, J. J., JR., CHOAY, J., LORMEAU, J.-C., PETITOU, M., SACHE, E. AND KARNOVSKY, M. J.: Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. II. Evidence for a pentasaccharide sequence that contains a 3-O sulfate group. J. Cell Biol. 102: 1979-1984, 1986.
12. CHANG, S.-W. AND VOELKEL, N. F.: Charge-related lung microvascular injury Am. Rev. Respir. Dis. 139: 534-545, 1989.
13. CHOPRA, L. C., TWORT, C. H. C., WARD, J. P. T. AND CAMERON, I. R.: Effects of heparin on inositol 1,4,5-triphosphate and guanosine 5′-O-(3-thio triphophate) induced calcium release in cultured smooth muscle cells from rabbit trachea. Biochem. Biophys. Res. Commun. 163: 262-268, 1989.
14. COYLE, A. J., ACKERMAN, S. J., BURCH, R., PROUD, D. AND IRVIN, C. G.: Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation J. Clin. Invest. 95: 1735-1740, 1995.
15. DELCLAUX, C., DELACOURT, C., D'ORTHO, M.-P., BOYER, V., LAFUMA, C. AND HARF, A.: Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am. J. Respir. Cell Mol. Biol. 14: 288-295, 1996.
16. DIAMANT, Z., TIMMERS, M. C., VAN DER VEEN, H., PAGE, C. P., VAN DER MEER, F. J. AND STERK, P. J.: Effect of inhaled heparin on allergen-induced early and late asthmatic responses in patients with atopic asthma. Am. J. Respir. Crit. Care Med. 153: 1790-1795, 1996.
17. 2 muscarinic receptor function in antigen challenged guinea-pigs. Am. J. Respir. Cell Mol. Biol. 12: 320-328, 1995.
18. 2-dependent hydroxyl radical production during ischemia-reperfusion lung injury. Am. J. Physiol. 265 (Lung Cell. Mol. Physiol. 9): L279-L285, 1993.
19. FRIEDRICHS, G. S., KILGORE, K. S., MANLEY, P. J., GRALINSKI, M. R. AND LUCHESI, B. R.: Effects of heparin and N-acetyl heparin on ischemia/reperfusion-induced alterations in myocardial function in the rabbit isolated heart. Circ. Res. 75: 701-710, 1994.
20. 2 muscarinic receptors in antigen challenged guinea-pigs is restored by heparin and poly-1-glutamate. J. Clin. Invest. 90: 2292-2298, 1992.
21. GHOSH, T. K., Lis, P. S., MULLANEY, J. M., EBERT, C. L. AND GILL, D. L.: Competitive, reversible, and potent antagonism of inositol 1,4,5-triphosphate-activated calcium release by heparin. J. Biol. Chem. 263: 11075-11079, 1988.
22. GOSSAGE, J. R., KURATOMI, Y., DAVIDSON, J. M., LEFFERTS, P. L. AND SNAPPER, J. R.: Neutrophil elastase inhibitors, SC-37698 and SC-39026, reduce endotox-in-induced lung dysfunction in awake sheep. Am. Rev. Respir. Dis. 147: 1371-1379, 1993.
23. Quo, Y. AND CONRAD, H. E.: Analysis of oligosaccharides from heparin by reversed-phase ion-pairing high-performance liquid chromatography. Anal. Biochem. 178: 54-62, 1988.
24. HATHAWAY, G. M., LUBBEN, T. H. AND TRAUGH, J. A.: Inhibition of casein kinase II by heparin. J. Biol. Chem. 255: 8038-8041, 1980.
25. HERNANDEZ, L. A., GRISHAM, M. B., TWOHIG, B., ARFORS, K.-E., HARLAN, J. M. AND GRANGER, D. N.: Role of neutrophils in ischemia-reperfusion-induced microvascular injury. Am. J. Physiol. 253 (Heart Circ. Physiol. 22): H699-H703, 1987.
26. HOCKING, D. C., FERRO, T. J. AND JOHNSON, A.: Dextran sulfate inhibits PMN-dependent hydrostatic pulmonary edema induced by tumor necrosis factor. J. Appl. Physiol. 70: 1121-1128, 1991.
27. HOCKING, D., FERRO, T. J. AND JOHNSON, A.: Dextran sulfate and heparin sulfate inhibit platelet-activating factor-induced pulmonary edema. J. Appl. Physiol. 72: 179-185, 1992.
28. INOUE, Y. AND NAGASAWA, K.: Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol. Carbohydr. Res. 46: 87-95, 1976.
29. 2 receptor. J. Clin. Invest. 91: 1314-1318, 1993.
30. JAMES, A. L., PARE, P. D. AND HOGG, J. C.: The mechanics of airway narrowing in asthma. Am. Rev. Respir. Dis. 130: 242-246, 1989.
31. JAQUES, L. B.: Heparins: Anionic polyelectrolyte drugs. Pharmacol. Rev. 31: 99-166, 1980.
32. JASEJA, M., REJ, R. N., SAURIOL, F. AND PERLIN, A. S.: Novel regio-and stereo-selective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence. Can. J. Chem. 67: 1449-1456, 1989.
33. JESTY, J. AND NEMERSON, Y.: The activation of bovine coagulation factor X. Methods Enzymol. 45: 95-107, 1976.
34. KAO, R. C., WEHNER, N. G., SKUBITZ, K. M., GRAY, B. H. AND HOIDAL, J. R.: Proteinase 3: A distinct human polymorphonuclear leukocyte proteinase that produces emphysema in hamsters. J. Clin. Invest. 82: 1963-1973, 1988.
35. KENNEDY, T. P., RAO, N. V., HOPKINS, C., PENNINGTON, L., TOLLEY, E. AND HOIDAL, J. R.: Role of reactive oxygen species in reperfusion injury of the rabbit lung. J. Clin. Invest. 83: 1326-1335, 1989.
36. KILFEATHER, S. A., TAGOE, S., PEREZ, A. C., OKONA-MENSA, K., MATIN, R. AND PAGE, C. P.: Inhibition of serum-induced proliferation of bovine tracheal smooth muscle cells in culture by heparin and related glycosaminoglycans. Br. J. Pharmacol. 114: 1442-1446, 1995.
37. LEE, C., FEIN, A., LIPPMANN, M., HOLTZMAN, H., KIMBEL, P. AND WEINBAUM, G.: Elastolytic activity in pulmonary lavage fluid from patients with adult respiratory-distress syndrome. N. Engl. J. Med. 304: 192-196, 1981.
38. LEVY, L. AND PETRACEK, F. J.: Chemical and pharmacological studies on N-resulfated heparin. Proc. Soc. Exp. Biol. Med. 109: 901-905, 1962.
39. LEY, K., CERRITO, M. AND ARFORS, K.-E.: Sulfated polysaccharides inhibit leukocyte rolling in rabbit mesentery venules. Am. J. Physiol. 260: 1667-1673, 1991.
40. LIDER, O., MEKORI, Y. A., MILLER, T., BAR-TANA, R., VLODAVSKY, I., BAHARAV, E., COHEN, I. R. AND NAPARSTEK, Y.: Inhibition of T lymphocyte heparanase by heparin prevents T cell migration and T cell-mediated immunity. Eur. J. Immunol. 20: 493-499, 1990.
41. LUNDGREN, J. D., RIEVES, R. D., MULLOL, J., LOGAN, C. AND SHELHAMER, J.: The effect of neutrophil protenase enzymes on the release of mucus from feline and human airway cultures. Respir. Med. 88: 511-518, 1994.
42. LUNGARELLA, G., MENEGAZZI, R., GARDI, C., SPESSOTTO, P., MARHERITA DE SANTI, M.; BERTONCIN, P., PATRIARCA, P., CALZONI, P. AND ZABUCCHI, G.: Identification of elastase in human eosinophils: immunolocalization, isolation, and partial characterization. Arch. Biochem. Biophys. 292: 128-135, 1992.
43. MACCARANA, M., CASU, B. AND LINDAHL, U.: Minimal sequence in heparin/ heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem. 268: 23898-23905, 1993.
44. MARCUM, J. A. AND ROSENBERG, R. D.: The biochemistry, cell biology, and pathophysiology of anticoagulantly active heparin-like molecules of the vessel wall. In Heparin. Chemical and Biological Properties, Clinical Applications. ed. by D. A. Lane and U. Lindahl, pp. 275-294, CRC Press, Inc., Boca Raton, FL, 1989.
45. MCELVANEY, N. G., NAKAMURA, H., BIRRER, P., HEBERT, C. A., WONG, W. L., ALPHONSO, M., BAKER, J. B., CATALANO, M. A. AND CRYSTAL, R. G.: Modulation of airway inflammation in cystic fibrosis. In vivo supression of interleukin-8 levels on the respiratory epithelial surface by aerosolization of recombinant secretory leukoprotease inhibitor. J. Clin. Invest. 90: 1296-1301, 1992.
46. MEIER, H. L., SCHULMAN, E. S., HECK, L. W., MACGLASHAN, D., NEWBALL, H. H. AND KAPLAN, A. P.: Release of elastase from purified human lung mast cells and basophils. Identification as a Hageman factor cleaving enzyme. Inflammation 13: 295-308, 1989.
47. MILETICH, J. P.: Activated partial thromboplastin time. In Williams Hematology, 5th ed., ed. by E. Beutler, M. A. Lichtman, B. S. Coller and T. J. Kipps, pp. L85-L87, McGraw-Hill, Inc., New York, 1995.
48. MINETTE, P. AND BARNES, P. J.: Prejunctional inhibitory muscarinic receptors in cholinergic nerve terminals in human and guinea-pig airways. J. Appl. Physiol. 64: 2532-2537, 1988.
49. NICKLIN, M. J. H. AND BARRETT, A. J.: Inhibition of cysteine proteinases and dipeptidyl peptidase I by egg-white cystatin. Biochem. J. 223: 245-253, 1984.
50. NICOLINI, F. A., MEHTA, J. L., NICHOLS, W. W., DONNELLY, W. H., LUOSTARINEN, R. AND SALDEEN, T. G.: Leukocyte elastase inhibition and t-PA-induced coronary artery thrombolysis in dogs: Beneficial effect on myocardial histology. Am. Heart J. 122: 1245-1251, 1991.
51. OTTLINGER, M. E., PUKAC, L. A. AND KARNOVSKY, M. J.: Heparin inhibits mitogen-activated protein kinase activation in intact rat vascular smooth muscle cells. J. Biol. Chem. 268: 19173-19176, 1993.
52. OWEN, C. A., CAMPBELL, M. A., BOUKEDES, S. S., STOCKLEY, R. A. AND CAMPBELL, E. J.: A discrete subpopulation of human monocytes expresses a neutrophil-like proinflammatory (P) phenotype. Am. J. Physiol. 267(Lung Cell. Mol. Physiol. 11): L775-L785, 1994.
53. RAO, N. V., KENNEDY, T. P., RAO, G., KY, N. AND HOIDAL, J. R.: Sulfated polysaccharides prevent human leukocyte elastase-induced lung injury and emphysema in hamsters. Am. Rev. Respir. Dis. 142: 407-412, 1990.
54. REDINI, F., TIXIER, J.-M., PETITOU, M., CHOAY, J., ROBERT, L. AND HORNEBECK, W.: Inhibition of leukocyte elastase by heparin and its derivatives. Biochem. J. 252: 515-519, 1988.
55. REJ, R., JASEJA, M. AND PERLIN, A. S.: Importance for blood anticoagulant activity of a 2-sulfate group on L-iduronic acid residues in heparin. Thromb. Haemostat. 61: 540, 1989.
56. SIMON, R. H., DEHART, P. D. AND TODD, R. F., III: Neutrophil-induced injury of rat pulmonary alveolar epithelial cells. J. Clin. Invest. 78: 1375-1386, 1986.
57. SKINNER, M. P., LUCAS, C. M., BURNS, G. F., CHESTERMAN, C. N. AND BERNDT, M. C.: GMP-140 binding to neutrophils is inhibited by sulfated glycans. J. Biol. Chem. 266: 5371-5710, 1991.
58. SOMMERHOFF, C. P., NADEL, J. A., BASBAUM, C. B. AND CAUGHEY, G. H.: Neutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway serous cells. J. Clin. Invest. 85: 682-689, 1990.
59. STARCHER, B. C. AND GALIONE, M. J.: Purification and comparison of elastins from different animal species. Anal. Biochem. 74: 411-447, 1976.
60. STEVENS, R. B., WANG, Y. L., KAJI, H., LLOVERAS, J., DALMASSO, A., BACH, F. H., RUBINSTEIN, P., SUTHERLAND, D. E. R. AND PLATT, J. L.: Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival. Transplant. Proc. 25: 382, 1993.
61. STONE, P. U., FRANZBLAU, C. AND KAGAN, H. M.: Proteolysis of insoluble elastin. Methods Enzymol. 82: 588-605, 1982.
62. TEIEN, N. A. AND LIE, M.: Evaluation of an amidolytic heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb. Res. 10: 399-410, 1977.
63. THOMPSON, B. T., SPENCE, C. R., JANSSENS, S. P., JOSEPH, P. M. AND HALES, C. A.: Inhibition of hypoxic pulmonary hypertension by heparins of differing in vitro antiproliferative potency. Am. J. Respir. Crit. Care Med. 149: 1512-1517, 1994.
64. UNITED STATES PHARMACOPEIAL CONVENTION: Heparin Sodium. In United States Pharmacopeia, pp. 736-738, United States Pharmacopeial Convention, Inc., Rockville, MD, 1995.
65. WEILER, J. M., EDENS, R. E., LINHARDT, R. J. AND KAPELANSKI, D. P.: Heparin and modified heparin inhibit complement activation in vivo. J. Immunol. 148: 3210-3215, 1992.
66. WRIGHT, T. C., CASTELLOT, J. J., DIAMOND, J. R. AND KARNOVSKY, M. J.: Regulation of cellular proliferation of heparin and heparan sulfate. In Heparin. Chemical and Biological Properties, Clinical Applications, ed. by D. A. Lane and U. Lindahl, pp. 295-316, CRC Press, Inc., Boca Raton, FL, 1989a.
67. WRIGHT, T. C., JR., CASTELLOT, J. J., JR., PETITOU, M., LORMCOU, J.-C., CHOAY, J. AND KARNOVSKY, M. J.: Structural determinants of heparin's growth inhibitory activity. Interdependent of oligosaccharide size and charge. J. Biol. Chem. 264: 1534-1542, 1989b.
68. ZIMMERMAN, B. J. AND GRANGER, D. N.: Reperfusion-induced leukocyte infiltration: Role of elastase. Am. J. Physiol. 259(Heart Circ. Physiol. 28): H390-H394, 1990.